


RSC-BMCS Hall of Fame and Medal 2025

Announcement of Winner



The BMCS is delighted to announce that **Alessio Ciulli** (University of Dundee) will be the 2025 inductee to its Hall of Fame, and the recipient of the associated medal.

Alessio Ciulli is internationally recognised as one of the founding fathers of the Targeted Protein Degradation (TPD) field. He has made several key contributions which have helped define the rules of the field and expand its boundaries, culminating in the establishment of a new therapeutic modality. His group published the first crystal structure of a protein-PROTAC-E3 ligase ternary complex, were the first to demonstrate that PROTACs could be selective among highly homologous proteins, and developed an understanding of protein-ligase cooperativity and its impact on degradation. He discovered the CRBN midi construct, which enabled crystallography with CRBN, and also developed BromoTag technology.

Alessio has made major contributions to the UK's prominent position in the TPD field and he is seen as one of the top scientists and thought-leaders internationally in this exciting and important area. He is a scientific co-founder of Amphista Therapeutics, which is based on his scientific research. He has also established the Centre for Targeted Protein Degradation (CeTPD) and his collaboration with Boehringer Ingelheim has led to the first PROTACs that degrade many of the oncogenic mutants of the extremely challenging protein KRAS.

The purpose of this award is to recognize prominent chemists for outstanding, sustained, and significant scientific impact, or contributions to any area of interest to the BMCS, e.g., medicinal chemistry, agriscience, bioorganic chemistry, chemical biology.

